Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
AI superintelligence startup promises new drug discoveries
This article by Greg Licholai discusses how AI is revolutionising drug discovery, with companies like Lila Sciences and Recursion Pharmaceuticals leading the charge by using AI to accelerate scientific breakthroughs. Lila focuses on creating "scientific superintelligence" through autonomous labs, while Recursion maps human biology to discover new treatments faster.
-
ICON discusses how AI is changing clinical trial recruitment and diversity
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
-
AI-powered precision measures: A golden opportunity for clinical research
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce operational efficiencies. AI-powered digital measures are being developed and validated to better define disease, patients, and drug efficacy.
-
AI’s transformative role in drug discovery and development
In the Irish Times Life Sciences and Stem supplement, ICON’s CIO Tom O’Leary discussed AI is transforming drug development across a range of specific use cases, from discovery to clinical trials and post-marketing.
-
How AI can manage the risks and costs of postmarketing requirements
Postmarketing requirements (PMRs) for drug development are commonly required to gather data on a product’s longer-term safety, efficacy and optimal use. Carefully applied AI and machine learning offers the potential for better management of PMRs.
-
Us and it
This article by Gerard Quinn, Vice President of IT Innovation and Informatics, which appeared in PharmaTimes Magazine, delves into how AI is transforming clinical trials by improving efficiency, accelerating timelines, and enhancing decisions across the clinical development process.
-
Streamlining bioprocesses with automation
In this article from BioPharm International, Ronan Fox, Senior Vice President, IT R&D, provides commentary on the evolving role of automation in biopharmaceutical development.
-
Human-enabled AI driving enhancements in clinical trial site selection
In this piece from Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics explores the improvements in site selection that human-enabled AI is delivering.
-
Outsourcing analytical testing: AI could transform analytical labs
In this article from Drug Development & Delivery, Suzanne Jansen, Head of QC Laboratory, discusses the importance of faster data turnaround within the analytical lab to facilitate adaptive dosing decisions that will benefit all stages of clinical trials.
-
AI has the power to revolutionise drug discovery and design
In this article from the Irish Times, Gerard Quinn, VP of IT Innovation and Informatics provides insight on how artificial intelligence can support the drug development process in order to deliver new treatments to more people, faster.
